Jun 29, 2021 / 08:30PM GMT
Operator
Thank you for standing by, and welcome to the Iovance Biotherapeutics update call. (Operator Instructions)
Please be advised that today's conference may be recorded. (Operator Instructions)
I would now like to hand the conference over to your host, Sara Pellegrino. Please go ahead.
Sara Pellegrino - Iovance Biotherapeutics, Inc. - VP of IR & Public Relations
Thank you. Good afternoon, and thank you for joining our conference call to discuss the initial clinical data for our TIL cell therapy LN-145 in metastatic non-small cell lung cancer, or NSCLC.
For today's agenda, our Interim President and CEO, Fred Vogt, will do a brief introduction; Dr. Friedrich Finckenstein, our Chief Medical Officer; and Dr. Madan Jagasia, our Senior Vice President, Medical Affairs, will then highlight the clinical data, and we will hold a question-and-answer session.
Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's clinical results,
Iovance Biotherapeutics Inc to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer- Conference Call Transcript
Jun 30, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers